Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.

Molecular cancer therapeutics - 1 Jul 2016

Okada-Iwasaki Ryoko, Takahashi Yuichi, Watanabe Yasuo, Ishida Hiroshi, Saito Jun-Ichi, Nakai Ryuichiro, Asai Akira

Abstract excerpt

The Wnt/β-catenin pathway is a well-known oncogenic pathway. Its suppression has long been considered as an important challenge in treating cancer patients. Among colon cancer patients in particular, most patients carry an adenomatous polyposis coli (APC) mutation that leads to an aberration of Wnt/β-catenin pathway. To discover the small molecule inhibitors of the Wnt/β-catenin pathway, we conducted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Axin Protein
Share to beta Catenin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colonic Neoplasms

Share to Genes, APC

Share to Molecular Conformation

Share to Protein Stability

Share to RNA, Small Interfering

Share to Wnt Signaling Pathway

Source

Identifiers

PMID: 27196752
DOI: 10.1158/1535-7163.MCT-15-0938

Genes

TNKS
APC
DLD
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.PMID 27196752Read ↗

A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.Semantic proximity Read ↗

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal CancerSemantic proximity Read ↗

Small Molecule Destabilizer of β-Catenin and Ras Proteins Antagonizes Growth of K-Ras Mutation-Driven Colorectal Cancers Resistant to EGFR Inhibitors.Semantic proximity Read ↗

The potential of targeting Wnt/β-catenin in colon cancerSemantic proximity Read ↗

Targeting Wnt/β-Catenin Pathway for Drug TherapySemantic proximity Read ↗

Targeting the Wnt signaling pathway in colorectal cancer.Semantic proximity Read ↗

Blocking the Wnt/β‑catenin signaling pathway to treat colorectal cancer: Strategies to improve current therapies (Review)Semantic proximity Read ↗

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitorsSemantic proximity Read ↗

KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer.Semantic proximity Read ↗

Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer.Semantic proximity Read ↗

Tankyrase inhibition sensitizes cells to CDK4 blockade.Semantic proximity Read ↗

Wnt signaling as a therapeutic target for cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.